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ipating in the Amplatzer Cardiac Plug multicenter study were requested to submit their post-procedural
transesophageal echocardiograms for independent adjudication. Thirteen of 22 centers contributed all
their post-procedural echocardiograms, which included 344 from 605 consecutive patients. These im-
ages were submitted to a core laboratory and reviewed by 2 independent experts for peri-device leak,
device-associated thrombus, device embolization, device migration, left atrial appendage thrombus, and
left atrial thrombus. Clinical events were prospectively collected by each center. RESULTS Of the 344
transesophageal echocardiograms, 339 were deemed analyzable. Patients’ mean age was 74.4 ± 7.5 years,
and 67.3% were men. The mean CHADSscore was 2.7 ± 1.3, the mean CHADS-VASc score was 4.3 ±
1.5, and the mean HAS-BLED score was 3.0 ± 1.2. Amplatzer Cardiac Plug implantation was successful
in all patients. Periprocedural major adverse events occurred in 2.4%. Median clinical follow-up duration
was 355 days (range 179 to 622 days). Follow-up transesophageal echocardiography was performed after
a median of 134 days (range 88 to 227 days). Device-associated thrombus was observed in 3.2% and peri-
device leak in 12.5% (5.5% minimal, 5.8% mild, 0.6% moderate, 0.6% severe). Neither device-associated
thrombus nor peri-device leak was associated with an increased risk for cardiovascular events. Indepen-
dent predictors of device-associated thrombus were smoking (odds ratio: 5.79; p = 0.017) and female sex
(odds ratio: 4.22; p = 0.027). CONCLUSIONS Following successful left atrial appendage closure with
the Amplatzer Cardiac Plug, the presence of peri-device leak was relatively low, and device-associated
thrombus was infrequent. Neither was associated with increased risk for thromboembolism.
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ABSTRACT
OBJECTIVES Routine device surveillance after successful left atrial appendage closure is recommended to evaluate
for intermediate to late complications. The aim of this study was to assess the incidence and clinical impact of these
complications on cardiovascular events.
METHODS Centers participating in the Amplatzer Cardiac Plug multicenter study were requested to submit their post-
procedural transesophageal echocardiograms for independent adjudication. Thirteen of 22 centers contributed all their
post-procedural echocardiograms, which included 344 from 605 consecutive patients. These images were submitted to a
core laboratory and reviewed by 2 independent experts for peri-device leak, device-associated thrombus, device
embolization, device migration, left atrial appendage thrombus, and left atrial thrombus. Clinical events were prospec-
tively collected by each center.
RESULTS Of the 344 transesophageal echocardiograms, 339 were deemed analyzable. Patients’ mean age was
74.4  7.5 years, and 67.3% were men. The mean CHADS2 score was 2.7  1.3, the mean CHA2DS2-VASc score was
4.3  1.5, and the mean HAS-BLED score was 3.0  1.2. Amplatzer Cardiac Plug implantation was successful in all pa-
tients. Periprocedural major adverse events occurred in 2.4%. Median clinical follow-up duration was 355 days (range 179
to 622 days). Follow-up transesophageal echocardiography was performed after a median of 134 days (range 88 to
227 days). Device-associated thrombus was observed in 3.2% and peri-device leak in 12.5% (5.5% minimal, 5.8% mild,
0.6% moderate, 0.6% severe). Neither device-associated thrombus nor peri-device leak was associated with an
increased risk for cardiovascular events. Independent predictors of device-associated thrombus were smoking
(odds ratio: 5.79; p ¼ 0.017) and female sex (odds ratio: 4.22; p ¼ 0.027).
CONCLUSIONS Following successful left atrial appendage closure with the Amplatzer Cardiac Plug, the presence of
peri-device leak was relatively low, and device-associated thrombus was infrequent. Neither was associated with increased risk
for thromboembolism. (J Am Coll Cardiol Intv 2017;10:391–9) © 2017 by the American College of Cardiology Foundation.
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L eft atrial appendage (LAA) closure isincreasingly performed as an alterna-tive to oral anticoagulation (OAC) for
stroke prevention in patients with atrial
ﬁbrillation (AF), especially those with con-
traindications for OAC. The rationale and
mechanism of LAA closure in stroke preven-
tion hinge on the observation from transeso-
phageal echocardiographic (TEE) studies that
about 91% of thrombi were located in the
LAA in the setting of nonvalvular AF (1). These
thrombi were implicated as important sources for car-
dioembolic strokes with AF, and thus, multinational
guidelines endorse OAC for patients at high stroke
risk on the basis of risk predictions scores, such as
CHA2DS2-VASc (2,3). However, despite the wide-
spread availability of novel and direct OAC, 30% to
40% of patients with guideline indications for OAC
do not receive anticoagulation, because of contraindi-
cations, intolerance, high bleeding risk, or patient
refusal (4). Thus, local targeted therapy to exclude
or excise the LAA as a potential thromboembolic
source has been explored since 1949 (5), with the ﬁrst
minimally invasive endovascular device LAA closure
performed in 2001 by Sievert (6).
Although endovascular LAA closure is an attractive
alternative to lifelong OAC, with recent randomized
trials establishing safety and efﬁcacy in comparison
with warfarin (7,8), there remain important device-
associated technical requirements post-implantation
to minimize long-term thromboembolic risks. In
particular, device-associated thrombus and incom-
plete closure (i.e., presence of peri-device leak) have
been implicated as potential causes of late thrombo-
embolic events after initial technically successful
LAA closure. Therefore, routine device surveillance
at intermediate follow-up (1 to 6 months post-
implantation) is strongly recommended, which pro-
vides the opportunity to assess for device-associated
thrombus, peri-device leak, device positioning,
surrounding structures, and pericardial effusion.
The Amplatzer Cardiac Plug (ACP) (St. Jude Medi-
cal, Maple Grove, Minnesota) is 1 of the leading
endovascular LAA closure devices available globally
in >70 countries. The procedural and clinical out-
comes of 1,047 patients who underwent ACP im-
plantation at 22 centers were recently reported (9).
We sought to assess the incidence and clinical impact
of device-associated thrombus and peri-device leak
in the subset of patients in this multicenter ex-
perience who underwent TEE follow-up after ACP
implantation.
METHODS
The primary results of the ACP multicenter experi-
ence were previously reported (9). In brief, this study
included 1,047 consecutive patients with nonvalvular
AF who underwent LAA closure with the ACP at 22
centers in Europe and Canada from December 2008 to
November 2013. Data were prospectively collected
from each center, transferred to a dedicated database,
and analyzed retrospectively. For this substudy,
centers participating in the ACP multicenter study
were requested to submit their post-procedural
transesophageal echocardiograms for independent
adjudication. Thirteen of 22 centers contributed all
their post-procedural surveillance echocardiograms,
which included a total of 344 from 605 consecutive
patients. These echocardiograms were submitted to a
core laboratory (Cardialysis BV, Rotterdam, the
Netherlands) and were reviewed by a clinical events
committee. The clinical events committee was
composed of independent experts who were not
study investigators and not employed by St. Jude
Medical. A quorum of 2 experts reviewed and adju-
dicated all TEE ﬁndings. In case of disagreement, a
third clinical events committee member would then
review and make ﬁnal decision.
TEE DEFINITIONS. All transesophageal echocardio-
grams were reviewed in accordance with pre-
speciﬁed deﬁnitions for the presence of peri-device
leak, device-associated thrombus, device emboliza-
tion, device migration, LAA thrombus, and left atrial
thrombus.
Per i -dev ice leak. Color-ﬂow Doppler was used to
assess for residual ﬂow (leak) around the device into
the LAA. Peri-device leak was deﬁned as the presence
of a color jet around the device lobe that was detected
in at least 2 frames in the same location (frames could
be nonsequential). The severity of leak was graded as
follows: severe, >5-mm-diameter jet; moderate, 3- to
5-mm-diameter jet; mild, 1- to 3-mm-diameter jet;
minimal, <1-mm-diameter jet; and none, no visible
leak seen on all available views.
SEE PAGE 400
ABBR EV I A T I ON S
AND ACRONYMS
ACP = Amplatzer Cardiac Plug
AF = atrial ﬁbrillation
LAA = left atrial appendage
OAC = oral anticoagulation
TEE = transesophageal
echocardiographic
TIA = transient ischemic attack
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Device embol izat ion . The device had moved
entirely outside of the LAA.
Device migrat ion . The device had moved proximal
to the circumﬂex artery but still within the LAA,
typically with the appearance of a noncompressed
lobe, ﬂat disc, no separation between disc and lobe,
signiﬁcant or severe leak, and increased mobility of
the device.
Thrombus . On TEE imaging, an ACP-associated
thrombus or LAA or left atrial thrombus was deﬁned
as a well-circumscribed, uniformly consistent, echo-
reﬂective mass of different texture from the ACP,
the LAA, or the left atrial wall. A thrombus was
deﬁned as mobile when there was clear motion in at
least 3 sequential TEE frames.
Device success . Successful LAA occlusion was
deﬁned as the absence of moderate or severe leak and
no signs of device embolization or migration.
CLINICAL EVENTS AND FOLLOW-UP. All centers
provided clinical details for every reported major
adverse event. Periprocedural major adverse events
within 7 days post-procedure or before hospital
discharge were deﬁned according to the Valve Aca-
demic Research Consortium criteria (10) and inclu-
ded death, myocardial infarction, stroke, transient
ischemic attack (TIA), systemic embolization, air
embolization, device embolization, signiﬁcant
pericardial effusion or cardiac tamponade, and major
bleeding. Clinical follow-up through patient visit or
phone contact was performed according to individual
center or operator protocol. Follow-up adverse events
were deﬁned according to the Valve Academic
Research Consortium criteria and included death
(cardiovascular or noncardiovascular), stroke, TIA,
systemic embolism, and major bleeding (10). Antith-
rombotic therapy recommendation by the device
manufacturer after LAA closure was aspirin 80 to 100
mg/day and clopidogrel 75 mg/day for 1 to 3 months,
followed by aspirin 80 to 100 mg/day for at least
another 3 months. However, the choice and duration
of antithrombotic therapy were individualized on the
basis of physician preference and recorded at admis-
sion and last follow-up visit.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD and categorical variables as
frequencies and percentages. Variables with skewed
distributions are presented as median (interquartile
range). Continuous variables were compared using
the independent-samples Student t test, and cate-
gorical variables were compared using the chi-square
or Fisher exact test. Stepwise logistic regression was
used to assess for univariate and multivariate
clinical predictors for device-associated thrombus,
peri-device leak, and major adverse events. A
2-sided p value <0.05 was considered to indicate
statistical signiﬁcance. Statistical analyses were
TABLE 1 Baseline Characteristics (n ¼ 339)
Age (yrs) 74.4  7.5
Male 228 (67.3%)
Height (cm) 170.2  9.0
Weight (kg) 79.4  15.7
BMI (kg/m2) 27.3  4.6
Diabetes mellitus 98 (28.9%)
Hypertension 290 (85.5%)
Smoking 26 (7.7%)
Dyslipidemia 107 (31.6%)
Prior stroke or TIA 122 (36.0%)
Prior TIA 28 (8.3%)
Prior peripheral embolism 19 (5.6%)
Carotid disease 23 (6.8%)
Coronary artery disease 117 (34.5%)
Prior myocardial infarction 45 (13.3%)
Prior PCI 84 (24.8%)
Prior CABG 28 (8.3%)
Congestive heart failure 87 (25.7%)
Renal failure 82 (24.2%)
Paroxysmal AF 118 (34.8%)
Permanent AF 189 (55.8%)
Persistent AF 32 (9.4%)
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CABG ¼ coronary artery bypass
grafting; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic
attack.
TABLE 2 Baseline Thromboembolic and Bleeding Risks (n ¼ 339)
CHADS2 score 2.7  1.3
CHA2DS2-VASc score 4.3  1.5
0
1 1 (0.3%)
2 6 (1.8%)
3 30 (8.8%)
4 68 (20.1%)
5 86 (25.4%)
6 83 (24.5%)
7 40 (11.8%)
8 16 (4.7%)
9 7 (2.1%)
Annual risk of thromboembolism (%) 5.3  2.6
HAS-BLED score 3.0  1.2
0
1 4 (1.2%)
2 36 (10.6%)
3 75 (22.1%)
4 121 (35.7%)
5 68 (20.1%)
6 27 (8.0%)
Annual major bleeding risk (%) 5.0  3.7
Values are mean  SD or n (%).
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performed using SPSS version 23 (IBM, Armonk,
New York).
RESULTS
Of the 344 follow-up transesophageal echocardio-
grams that were submitted to the core laboratory
for evaluation, 339 were deemed analyzable and
constituted the cohort of this substudy. Baseline
demographics are described in Table 1. Patients’ mean
age was 74.4  7.5 years, and 67.3% were men. The
mean CHADS2 score was 2.7  1.3, the mean CHA2DS2-
VASc score was 4.3  1.5, and the mean HAS-BLED
score was 3.0  1.2 (Table 2). Paroxysmal AF was
present in 34.8% of patients, and the remainder had
permanent or persistent AF. The majority had con-
traindications to OAC (Table 3), including 48.4% with
prior major bleeding, 18.6% with prior minor
bleeding, and 22.4% with HAS-BLED scores $3.
ACP implantation was successful in all cases, with
a mean ACP size of 24.2  3.7 mm, and 91.2% of pa-
tients required only 1 device attempt (Table 4).
Combined procedures were carried out in 20.9% of
LAA closure cases, including concomitant coronary
angiography, patent foramen ovale or atria septal
defect closure, AF ablation, or valvular intervention.
The mean length of hospital stay was 2.8  2.4 days.
Periprocedural major adverse events occurred in 2.4%
of patients, including mortality in 0%, stroke in 0.3%,
air embolism in 0.3%, cardiac tamponade in 0.9%,
device embolization in 0.3%, and major bleeding
in 0.9% (Table 5). Median clinical follow-up duration
was 355 days (range 179 to 622 days). Cardiovas-
cular death occurred in 0.6% of patients, non-
cardiovascular death in 2.1%, stroke in 0.9%, TIA
in 1.2%, and major bleeding in 1.2%. Antithrombotic
therapy use post–LAA closure was available in
255 patients; of these, 159 were on dual-antiplatelet
therapy, 79 were on single-antiplatelet therapy,
16 were on OAC, and 1 was receiving no antith-
rombotic agent post–LAA closure.
Follow-up TEE imaging was performed after a
median of 134 days (range 88 to 227 days) (Table 6).
There was concordance in all adjudicated cases for
TABLE 3 Medical Reasons for Percutaneous Left Atrial
Appendage Closure (n ¼ 339)
Previous major bleeding 164 (48.4%)
Intracranial bleeding 62 (18.3%)
Gastrointestinal bleeding 62 (18.3%)
Previous minor bleeding 63 (18.6%)
Gastrointestinal bleeding 33 (9.7%)
Thromboembolism on OAC 37 (10.9%)
Liver disease 33 (9.7%)
Easy bruising 35 (10.3%)
Labile INR 26 (7.7%)
High fall risk 29 (8.6%)
PCI with stents 48 (14.2%)
Drug interactions 17 (5.0%)
High HAS-BLED score 76 (22.4%)
Baseline antithrombotic
None 19 (5.6%)
Aspirin 217 (64.0%)
Clopidogrel/prasugrel/ticagrelor 59 (17.4%)
Warfarin 87 (25.7%)
Direct OAC 9 (2.7%)
Heparin 62 (18.3%)
Values are n (%).
INR ¼ international normalized ratio; OAC ¼ oral anticoagulation; PCI ¼
percutaneous coronary intervention.
TABLE 4 Procedural Results (n ¼ 339)
Procedural success 339 (100%)
Procedural duration (min) 85.5  42.1
Fluoroscopy time (min) 18.2  12.1
Hospital length of stay (days) 2.8  2.4
Procedural anesthesia
General anesthesia 105 (31.0%)
Sedation only 52 (15.3%)
Local anesthesia only 156 (46.0%)
Procedural imaging
TEE 240 (70.8%)
ICE 36 (10.6%)
Fluoroscopy only 63 (18.6%)
Via transseptal puncture 308 (90.9%)
Via PFO 31 (9.1%)
Combined procedures: 71 (20.9%)
LAA þ PFO closure 23 (6.8%)
LAA þ ASD closure 3 (0.9%)
LAA þ AF ablation 6 (1.8%)
LAA þ coronary angiography 35 (10.3%)
LAA þ PCI 19 (5.6%)
LAA þ TAVR 3 (0.9%)
LAA þ MitraClip 1 (0.3%)
ACP size (mm) 24.2  3.7
16 13 (3.8%)
18 18 (5.3%)
20 25 (7.4%)
22 79 (23.3%)
24 66 (19.5%)
26 55 (16.2%)
28 42 (12.4%)
30 41 (12.1%)
One device attempted 309 (91.2%)
Two devices attempted 27 (8.0%)
Three devices attempted 2 (0.6%)
Four devices attempted 1 (0.3%)
Values are n (%) or mean  SD.
ACP ¼ Amplatzer Cardiac Plug; AF ¼ atrial ﬁbrillation; ASD ¼ atrial septal
defect; ICE ¼ intracardiac echocardiography; LAA ¼ left atrial appendage; PCI ¼
percutaneous coronary intervention; PFO ¼ patent foramen ovale; TAVR ¼
transcatheter aortic valve replacement; TEE ¼ transesophageal echocardiography.
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the presence of device-associated thrombus and the
presence and degree of peri-device leak by both
reviewers. In these adjudicated cases, device-
associated thrombus was observed in 3.2% of pa-
tients and peri-device leak in 12.5% (Figure 1). Of the
11 cases of device-associated thrombus, TEE imaging
was performed at a mean duration of 165  135 days
after LAA closure, and 4 cases were mobile thrombi.
Seven were treated with dual-antiplatelet therapy
post–LAA closure, 3 with clopidogrel alone post–LAA
closure, and 1 with OAC post–LAA closure. None of
these 11 cases resulted in stroke or TIA over a mean
follow-up period of 322  141 days. Of the leaks, 5.5%
were graded as minimal, 5.8% as mild, 0.6% as
moderate, and 0.6% as severe. There were 2 late de-
vice migrations observed (TEE imaging on days 119
and 189) and 2 late device embolizations (TEE imag-
ing on days 54 and 87).
Neither device-associated thrombus nor peri-
device leak (irrespective of severity) was associated
with an increased risk for cardiovascular events
(stroke, TIA, cardiovascular death, or overall mortal-
ity) (Table 7). In univariate and multivariate logistic
regression models, only smoking (odds ratio: 5.79;
p ¼ 0.017) and female sex (odds ratio: 4.22; p ¼ 0.027)
were independent predictors of device-associated
thrombus (Table 8). No independent predictors of
peri-device leak or cardiovascular events were
identiﬁed.
DISCUSSION
In this independently adjudicated TEE substudy of
the ACP multicenter experience, we found that the
incidence rates of device-associated thrombus and
peri-device leak were low, 3.2% and 12.5%, respec-
tively. The presence of neither device-associated
thrombus nor peri-device leak was associated with
adverse cardiovascular events.
Both device-associated thrombus and peri-device
leak are important technical limitations and device-
related complications following percutaneous LAA
closure. Thrombus on the left atrial side of the device
may embolize and cause stroke, TIA, or peripheral
embolization. Incomplete LAA closure with peri-
device leak results in an open pouch with residual
ﬂow into the LAA, which may cause turbulence in
blood ﬂow adjacent to the device and stagnant blood
in the residual LAA pouch. These may enhance
platelet adhesion and thrombus formation at the edge
of the device or within the LAA and subsequent
embolization of thrombus past the device into sys-
temic circulation.
Device-associated thrombus is thought to occur
predominantly on the nonendothelialized portion of
the exposed device, especially on protruding struc-
ture such as the threaded insert of the WATCHMAN
device and the proximal end screw of the ACP.
In a pre-clinical study with dogs (n ¼ 9) implanted
with WATCHMAN devices, white pannus cove-
red the left atrial surface of the device by 45 days,
and the neoendocardial covering was continuous
from the left atrial wall to the device, while inside
the device and the LAA, there was organizing
thrombus and resorbing ﬁbrin (11). In another canine
study comparing the WATCHMAN with the ACP
(n ¼ 6), there was complete neoendocardial coverage
of the WATCHMAN device at 28 days, but the ACP
TABLE 5 Amplatzer Cardiac Plug Procedural and Clinical Events
(n ¼ 339)
Major procedural (in-hospital or within 7 days) events
Death 0 (0%)
Stroke 1 (0.3%)
TIA 0 (0%)
Air embolism 1 (0.3%)
MI 0 (0%)
Cardiac tamponade 3 (0.9%)
Device embolization 1 (0.3%)*
Major bleed 3 (0.9%)
Composite procedural major adverse events 8 (2.4%)
Other procedural events
Pericardial effusion (no intervention required) 14 (4.1%)
Minor bleeding (hematoma) 10 (2.9%)
Mean long-term follow-up (days) and
clinical events
428.9  324.8
CV death 2 (0.6%)
Non-CV death 7 (2.1%)
Stroke 3 (0.9%)
TIA 4 (1.2%)
Major bleeding 4 (1.2%)
Minor bleeding 5 (1.5%)
Values are n (%) or mean  SD. *Embolized device was successfully snared
percutaneously.
CV¼ cardiovascular; MI¼myocardial infarction; TIA ¼ transient ischemic attack.
TABLE 6 Adjudicated Transesophageal Echocardiographic Results
(n ¼ 339)
Mean follow-up TEE performed (days) 198.2  181.3
Thrombus on device 11 (3.2%)
Peri-device leak (assessed in 311)
None 272 (80.2%)
Minor (<1 mm) 17 (5.0%)
Mild (1–3 mm) 18 (5.3%)
Moderate (>3 but #5 mm) 2 (0.6%)
Severe (>5 mm or multiple jets) 2 (0.6%)
Values are mean  SD or n (%).
TEE ¼ transesophageal echocardiography.
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had incomplete coverage on the disc surface, espe-
cially at the lower edge and end screw (12). Never-
theless, in another larger canine study (n ¼ 10), by 90
days there was complete coverage of the ACP atrial
surface by stable mature neointima, with diffuse
ingrowth of mature ﬁbrous connective tissue in
the device and within the surface neointima (13).
These preclinical studies provide some guidance
on the duration of antithrombotic therapy prior to
complete device endothelialization, but nonetheless,
there can be differences in such timing in humans
compared with dogs and even among individual
humans.
In reported real-world registries with the ACP,
varying incidence rates of device-associated
thrombus had been reported, ranging from 0% to
16% (14–19). However, these were generally small
series involving <50 to 100 patients, and routine de-
vice surveillance imaging was not done, so there may
have been potential bias of reporting. Even in series
in which routine device-surveillance imaging was
performed at follow-up, device-associated thrombus
incidence could still vary because of differences
in implantation technique (e.g., depth of device
implantation) and variation in the use of procedural
imaging to guide optimal implantation (e.g., lack of
procedural imaging to avoid noncoverage of proximal
lobes, recesses, and trabeculations that can be the
nidus for thrombus formation) (15–19). Therefore, the
reported incidence of device-associated thrombus in
small series may not accurately reﬂect the true
incidence.
In our series, 13 centers that participated in the
ACP multicenter experience contributed all their
follow-up TEE images for independent adjudication.
With this more rigorous systematic consecutive re-
view of surveillance TEE imaging, we found a 3.2%
incidence of device-associated thrombus with the
ACP device in a population of predominantly pa-
tients with contraindications to OAC who received
antiplatelet therapy following LAA closure. Of note,
this incidence is slightly lower than the reported
4.4% from the overall 1,047 patient cohort in the
ACP multicenter experience, in which not all trans-
esophageal echocardiograms were independently
adjudicated (9). This incidence is similar to that
reported with the WATCHMAN device in the ASAP
(ASA Plavix Feasibility Study With WATCHMAN
FIGURE 1 Examples of Device-Associated Thrombus and Peri-Device Leak With Amplatzer Cardiac Plug
(A) Thrombus on the left atrial side of the device (red arrow). (B) Thrombus resolved (green arrow) following treatment with oral anti-
coagulation. (C) Thrombus on the proximal end screw of the Amplatzer Cardiac Plug (red arrow). (D) A 3-mm peri-device leak on color-ﬂow
Doppler (red arrow).
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Left Atrial Appendage Closure Technology) study,
which was reported at 4% for patients with contra-
indications to OAC treated with dual-antiplatelet
therapy post–LAA closure (20). Similarly, the inci-
dence of device-associated thrombus was 4.2% in the
PROTECT AF (WATCHMAN Left Atrial Appendage
System for Embolic Protection in Patients With Atrial
Fibrillation) study, in which patients eligible for OAC
were treated with warfarin for 45 days plus aspirin
post–LAA closure (21). In our study, none of the
11 patients with device-associated thrombus had
stroke or TIA events, compared with 0.6% to 0.7%
in the PROTECT AF and ASAP studies (20,21).
In combination, these ﬁndings suggest that device-
associated thrombus may have low thromboem-
bolic risks, especially if adequately managed with
anticoagulation.
Peri-device leak may occur with any percutaneous
LAA closure devices, particularly because these de-
vices are circular, whereas LAA ostia are often not
round (they may be oval, triangular, footlike, tear-
drop shaped, etc.) (22). Devices with “single-lobe”
designs may have a higher incidence of peri-device
leak compared with devices with “lobe and disc” de-
signs, because the latter have 2 layers of barrier be-
tween the left atrium and LAA interface. Indeed, the
PROTECT AF study showed that WATCHMAN (a
single-lobe device) had a 32% incidence of peri-device
leak at 12 months (23). In contrast, our study showed a
numerically lower peri-device leak incidence of only
12.5% with ACP. The ACP device also has 2 layers of
polyester mesh sewn in the lobe and disc, which
together with the nitinol compressive seal of the
oriﬁce by the lobe and disc may explain the observed
lower rate of peri-device leak.
The potential consequences of incomplete seal
were exempliﬁed by surgical data in which incom-
plete closure increased the risk for LAA thrombus and
thromboembolic events (24,25). However, incomplete
seal with percutaneous devices does not appear to
have the same adverse consequences compared with
surgical LAA closure. In a post hoc subanalysis of
PROTECT AF, the presence of residual peri-device
ﬂow into the LAA was not associated with increased
risk for thromboembolism (23). Similarly, in our
study, the presence of peri-device leak, irrespective
of severity, did not increase the risk for thromboem-
bolic events. These ﬁndings are reassuring and sug-
gest that leaks <5 mm with percutaneous LAA closure
devices are probably safe and do not need further
intervention.
The data reviewed here relate to endovascular
LAA devices. Epicardial LAA devices, such as the
Lariat (SentreHEART, Redwood, California), appear
to have different mechanisms of leak and throm-
bus. In a study that compared the WATCHMAN
(n ¼ 219) with the Lariat (n ¼ 259), the prevalence of
device-associated thrombus was 3.7% with the
WATCHMAN versus 1.6% with the Lariat (p ¼ 0.23).
With regard to leak, the WATCHMAN device had a
higher incidence of leak (21% vs. 14%, p ¼ 0.019),
but more important, the mechanism of leak was
different, being peri-device (eccentric) with the
WATCHMAN but central (concentric or gunnysack)
with the Lariat device (26). The ACP is similar to the
WATCHMAN in terms of the mechanism of leak being
peri-device.
STUDY LIMITATIONS. Not all centers involved with
the ACP multicenter experience provided their
follow-up transesophageal echocardiograms to the
TABLE 8 Predictors of Device-Associated Thrombus
Univariate Model Multivariate Model
Hazard Ratio (95% CI) p Value Hazard Ratio (95% CI) p Value
Age (yrs) 0.98 (0.91–1.06) 0.592
Female 3.82 (1.10–13.35) 0.036 4.22 (1.18–15.10) 0.027
BMI (kg/m2) 0.97 (0.84–1.12) 0.686
Smoking 4.97 (1.24–20.02) 0.024 5.79 (1.37–24.38) 0.017
Hypertension 2.23 (0.59–8.98) 0.231
Dyslipidemia 0.54 (0.16–1.82) 0.320
Diabetes 0.48 (0.14–1.59) 0.228
CHA2DS2-VASc score 1.12 (0.76–1.65) 0.573
CHADS2 score 0.89 (0.55–1.45) 0.644
HAS-BLED score 0.96 (0.59–1.58) 0.884
ACP size 0.96 (0.82–1.13) 0.631
ACP ¼ Amplatzer Cardiac Plug; BMI ¼ body mass index; CI ¼ conﬁdence interval.
TABLE 7 Comparison of Clinical Events in Patients With Device-Associated Thrombus
or Peri-Device Leak
Stroke/TIA Stroke/TIA/CV Death Stroke/TIA/Death
Device thrombus (n ¼ 11) 0.0% 0.0% 0.0%
No device thrombus (n ¼ 321) 2.1% 2.7% 4.6%
p value 1.00 1.00 1.00
Any leak (n ¼ 39) 2.6% 2.6% 2.6%
No leak (n ¼ 272) 2.2% 2.9% 5.1%
p value 1.00 1.00 0.70
Leak: mild to severe (n ¼ 22) 0.0% 0.0% 0.0%
No leak: mild to severe (n ¼ 289) 2.4% 3.1% 5.2%
p value 1.00 1.00 0.61
Leak: moderate to severe (n ¼ 4) 0.0% 0.0% 0.0%
No leak: mod to severe (n ¼ 307) 2.3% 2.9% 4.9%
p value 1.00 1.00 1.00
Abbreviations as in Table 5.
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core laboratory for independent adjudication. This
could have created selection bias for scans that
were submitted for adjudication if there were
differences in outcomes among centers. We app-
roached all centers to submit their images, but not
all centers complied. However, the centers that did
participate submitted all follow-up echocardiograms,
thus minimizing selection bias on the adjudicated
images. Nevertheless, not all patients who under-
went ACP implantation at each participating center
underwent follow-up TEE imaging, as there were
variations in surveillance imaging practices accord-
ing to centers and physicians. Likewise, there were
differences in antithrombotic regimen post–LAA
closure according to physician preferences, and not
all centers reported the antithrombotic therapy and
duration administered. The majority of patients
received antiplatelet therapy post–LAA closure,
but this may have consisted of dual- or single-
antiplatelet therapy, for varying durations. The
management of device-associated thrombus, once
identiﬁed, was also not reported. In addition, TEE
visualization of what were deemed thrombus may
be due to pannus (general limitation of TEE assess-
ment for thrombus) and may explain the low clinical
event rate in this group.
CONCLUSIONS
Following successful LAA closure with the ACP, the
presence of peri-device leak was relatively low, and
device-associated thrombus was infrequent on adju-
dicated surveillance TEE imaging. Furthermore, both
device-associated thrombus and peri-device leak
were not associated with increased risk for thrombo-
embolism. Thus, the clinical impact of these ﬁndings
appears limited in the setting of routine clinical
practice and management.
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